BioSpace News Archive

Rhythm Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to setmelanotide for the treatment Alström syndrome. People living with Alström syndrome may experience an insatiable hunger, also known as hyperphagia, and severe

Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (“Anchiano”), a biopharmaceutical company focused on discovery and development of novel therapies to treat cancer, today reported financial results for the year ended December 31, 2019. Key Developments Entered into an exclusive worldwide collaboration and option to license agreement on September 20, 2019 with ADT Pharmaceuticals, LLC (“ADT”) to develop novel small-molecule pan-RAS inhibitors a

ReWalk Robotics, Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”), has announced the finalization of an agreement with a group of German statutory health insurer (SHI) to allow any eligible beneficiary with a spinal cord injury (SCI) in the country to seek procurement of a ReWalk 6.0 exoskeleton system.

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that it will present information on the edasalonexent program in Phase 3 development for the treatment of Duchenne muscular dystrophy (DMD) during the Muscular Dystrophy Association (MDA) Virtual Clinical Trials Session on Tuesday, March 24, 2020.

Legion Healthcare Partners is pleased to announce the addition of James Welsh, MD to its Scientific Advisory Board. Dr. Welsh is an Associate Professor of Radiation Oncology at The University of Texas MD Anderson Cancer Center.

E25Bio , innovators of rapid diagnostic tests, announced today that it has raised a $2 million financing from Khosla Ventures. Founded in 2018 and based out of The Engine at MIT, the company develops technology for rapid diagnosis of dangerous infectious diseases such as dengue, zika, and now the novel coronavirus.

Rapid and Scalable RT-PCR Assay is Pending Approval for Emergency Use Authorization - BGI’s test already has approvals through CE-IVD and China’s NMPA - Kits are currently being distributed to more than 50 countries and regions worldwide - Highly sensitive and quick test with 3-hour turnaround time

The Association for Molecular Pathology (AMP), the premier global, molecular diagnostics professional society, applauds US Senator Rand Paul (R-KY) for introducing new legislation to allow molecular pathology professionals to continue advancing and offering laboratory developed testing procedures (LDPs) for patient care.

As the global Coronavirus crisis grows, consumers are making significant changes to the way they interact with content and advertising across platforms.

ZOOM+Care has appointed a new Chief Growth Officer to its growing leadership team. Joining the company is Mike Payne, who previously served as an executive at Ancestry, Virta Health, and Omada Health..